PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome

Marie Passet; Nicolas Boissel; François Sigaux; Colombe Saillard; Mario Bargetzi; Ibrahima Ba; Xavier Thomas; Carlos Graux; Yves Chalandon; Thibaut Leguay; Etienne Lengliné; Johanna Konopacki; Samuel Quentin; Eric Delabesse; Marina Lafage-Pochitaloff; Cédric Pastoret; Nathalie Grardel; Vahid Asnafi; Véronique Lhéritier; Jean Soulier; Hervé Dombret; Emmanuelle Clappier; Group for Research on Adult ALL (GRAALL)

doi:10.1182/blood-2018-10-882142

PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome

Blood. 2019 Jan 17;133(3):280-284. doi: 10.1182/blood-2018-10-882142. Epub 2018 Dec 3.

Authors

Marie Passet^{1

2

3}, Nicolas Boissel^{2

4

5}, François Sigaux^{2

6}, Colombe Saillard⁷, Mario Bargetzi^{8

9}, Ibrahima Ba^{1

3}, Xavier Thomas¹⁰, Carlos Graux¹¹, Yves Chalandon^{9

12}, Thibaut Leguay¹³, Etienne Lengliné^{2

4

5}, Johanna Konopacki¹⁴, Samuel Quentin^{1

3}, Eric Delabesse¹⁵, Marina Lafage-Pochitaloff¹⁶, Cédric Pastoret¹⁷, Nathalie Grardel¹⁸, Vahid Asnafi¹⁹, Véronique Lhéritier²⁰, Jean Soulier^{1

2

3}, Hervé Dombret^{2

4

5}, Emmanuelle Clappier^{1

2

3}; Group for Research on Adult ALL (GRAALL)

Affiliations

¹ Hematology Laboratory, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
² University Paris Diderot, Paris, France.
³ INSERM U944/CNRS UMR7212, Institut Universitaire d'Hématologie, Paris, France.
⁴ Clinical Hematology Department, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
⁵ EA-3518, Institut Universitaire d'Hématologie, Paris, France.
⁶ Commissariat à l'Energie Atomique et aux Énergies Renouvelables, Saclay, France.
⁷ Service d'Hématologie 2, Institut Paoli-Calmettes, Marseille, France.
⁸ Onkologie/Hämatologie, Kantonsspital Aarau AG, Aarau, Switzerland.
⁹ Swiss Group for Clinical Cancer Research, Bern, Switzerland.
¹⁰ Hématologie Marcel Bérard, Centre Hospitalier Lyon Sud, Pierre Bénite, France.
¹¹ Service d'Hématologie, CHU UCL Mont Godine, Yvoir, Belgium.
¹² Division of Hematology, Department of Oncology, University Hospital and University of Geneva, Geneva, Switzerland.
¹³ Hématologie Clinique et Thérapies Cellulaires, Hôpital Haut-Lévêque, Pessac, France.
¹⁴ Service d'Hématologie, HIA Percy, Clamart, France.
¹⁵ Laboratory of Hematology, Institut Universitaire de Cancérologie de Toulouse, Toulouse, France.
¹⁶ Department of Genetics, Assistance Publique-Hôpitaux de Marseille, Aix Marseille University, Marseille, France.
¹⁷ Laboratory of Hematology, CHU Pontchaillou, Rennes, France.
¹⁸ Laboratory of Hematology, CHU Lille, Lille, France.
¹⁹ Laboratory of Onco-Haematology, Hôpital Necker Enfants-Malades, Assistance Publique-Hôpitaux de Paris, Paris, France; and.
²⁰ Coordination du Groupe GRAALL, Centre Hospitalier Lyon Sud, Lyon, France.

PMID: 30510083
DOI: 10.1182/blood-2018-10-882142

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Cohort Studies
Follow-Up Studies
Humans
Mutation*
Neoplasm Recurrence, Local / genetics
Neoplasm Recurrence, Local / pathology*
Neoplasm Recurrence, Local / therapy
PAX5 Transcription Factor / genetics*
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / classification*
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology*
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy
Prognosis
Stem Cell Transplantation
Survival Rate
Transplantation, Homologous

Substances

PAX5 Transcription Factor
PAX5 protein, human